Shufro Rose & Co. LLC Has $2.07 Million Holdings in Pfizer Inc. (NYSE:PFE)

Shufro Rose & Co. LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 71,746 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Shufro Rose & Co. LLC’s holdings in Pfizer were worth $2,066,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the third quarter worth approximately $30,000. GoalVest Advisory LLC raised its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer during the third quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new stake in Pfizer in the 4th quarter valued at $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of analyst reports. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.14 on Friday, hitting $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The company has a 50-day simple moving average of $26.96 and a 200 day simple moving average of $28.39. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $40.37. The company has a market capitalization of $143.83 billion, a PE ratio of 70.56, a PEG ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s revenue was down 41.3% compared to the same quarter last year. Sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.61%. Pfizer’s payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.